Vertex Pharmaceuticals Inc (VRTX)

09:56 AM

My 3 Favorite Stocks to Buy Right Now - Finviz

09:56 AM

09:30 AM

My 3 Favorite Stocks to Buy Right Now - The Motley Fool

09:30 AM

07:41 AM

Published on: 2025-11-16 06:41:39 - newser.com

07:41 AM

Nov 14, 2025

Will Vertex Pharmaceuticals Incorporated benefit from macro trends2025 Growth vs Value & Daily Volume Surge Trade Alerts - newser.com

Nov 14, 2025

Nov 14, 2025

Is Vertex Pharmaceuticals Incorporated stock a smart buy before Fed meetingJuly 2025 Intraday Action & Daily Volume Surge Trade Alerts - newser.com

Nov 14, 2025

Nov 14, 2025

Visual analytics tools that track Vertex Pharmaceuticals Incorporated performanceQuarterly Risk Review & Weekly Momentum Stock Picks - newser.com

Nov 14, 2025

Nov 14, 2025

Daiwa Securities Adjusts Price Target on Vertex Pharmaceuticals to $500 From $430, Maintains Buy Rating - MarketScreener

Nov 14, 2025

Nov 14, 2025

How Vertex Pharmaceuticals Incorporated (VX1) stock moves on employment dataWeekly Profit Summary & Step-by-Step Swing Trade Plans - newser.com

Nov 14, 2025

Nov 14, 2025

Is Vertex Pharmaceuticals Incorporated (VX1) stock a buy on weaknessPortfolio Update Report & Breakout Confirmation Trade Signals - newser.com

Nov 14, 2025

Nov 13, 2025

Exit strategy if you’re trapped in Vertex Pharmaceuticals IncorporatedMarket Movement Recap & Verified Technical Signals - newser.com

Nov 13, 2025

Nov 13, 2025

Evercore ISI Sticks to Its Buy Rating for Vertex Pharmaceuticals (VRTX) - The Globe and Mail

Nov 13, 2025

Nov 13, 2025

Vertex Pharmaceuticals Incorporated’s volatility index tracking explained2025 Retail Activity & Real-Time Volume Analysis - newser.com

Nov 13, 2025

Nov 12, 2025

Published on: 2025-11-12 14:18:38 - newser.com

Nov 12, 2025

Nov 12, 2025

Novartis, Vertex, More Optimizing Shots on Multiple Goals in Lucrative I&I Space - BioSpace

Nov 12, 2025

Nov 12, 2025

Vertex Pharmaceuticals’ Promising Cystic Fibrosis Study: A Potential Game-Changer - MSN

Nov 12, 2025

Nov 11, 2025

Vertex highlights growing Medicaid coverage for non-opioid painkiller Journavx (VRTX:NASDAQ) - Seeking Alpha

Nov 11, 2025

Nov 11, 2025

Transcript : Vertex Pharmaceuticals Incorporated Presents at UBS Global Healthcare Conference 2025, Nov-09-2025 through Nov-12-2025 - MarketScreener

Nov 11, 2025

Nov 11, 2025

Barclays Reaffirms Their Hold Rating on Vertex Pharmaceuticals (VRTX) - The Globe and Mail

Nov 11, 2025

Nov 10, 2025

The Bull Case for Vertex Pharmaceuticals (VRTX) Could Change Following Strong Kidney Data and Regulatory Progress - Yahoo Finance

Nov 10, 2025

Nov 10, 2025

Analysts Offer Insights on Healthcare Companies: Vertex Pharmaceuticals (VRTX), Alnylam Pharma (ALNY) and Insulet (PODD) - The Globe and Mail

Nov 10, 2025

Nov 10, 2025

Vertex Pharmaceuticals: Promising Growth in Renal Disease Market with Strong Clinical Data and Strategic Development - TipRanks

Nov 10, 2025

Nov 10, 2025

Vertex stock holds steady as Stifel maintains $445 price target By Investing.com - Investing.com UK

Nov 10, 2025

Nov 10, 2025

Vertex Pharmaceuticals’ Promising Renal Franchise Developments Justify Buy Rating - TipRanks

Nov 10, 2025

Nov 10, 2025

5 Insightful Analyst Questions From Vertex Pharmaceuticals's Q3 Earnings Call - Finviz

Nov 10, 2025

Nov 10, 2025

Vertex Pharma Q3 2025 Earnings: $3.08B Revenue, EPS $4.80, Updates GuidanceNews and Statistics - IndexBox

Nov 10, 2025

Nov 10, 2025

Published on: 2025-11-10 02:55:06 - newser.com

Nov 10, 2025

Nov 10, 2025

5 Insightful Analyst Questions From Vertex Pharmaceuticals’s Q3 Earnings Call - The Globe and Mail

Nov 10, 2025

Nov 09, 2025

Can machine learning forecast Vertex Pharmaceuticals Incorporated recoveryJuly 2025 Reactions & Daily Profit Focused Stock Screening - newser.com

Nov 09, 2025

Nov 09, 2025

Vertex Pharmaceuticals (VRTX) Reports Promising Results from RUB - GuruFocus

Nov 09, 2025

Nov 08, 2025

Vertex Unveils Positive 48-Week Data For Povetacicept In IgAN And PMN - Nasdaq

Nov 08, 2025

Nov 08, 2025

Transcript : Vertex Pharmaceuticals IncorporatedSpecial Call - MarketScreener

Nov 08, 2025

Nov 08, 2025

Vertex reports promising 48-week data for povetacicept in kidney diseases - Investing.com Canada

Nov 08, 2025

Nov 08, 2025

Vertex Presents Updated Phase 1/2 Data From RUBY-3 Study That Continue to Demonstrate Best-in-Class Potential for Povetacicept in Adults with IgA Nephropathy and Primary Membranous Nephropathy at American Society of Nephrology Kidney Week - Business Wire

Nov 08, 2025

Nov 07, 2025

VRTX: UBS Adjusts Vertex Pharmaceuticals Price Target to $546 | VRTX Stock News - GuruFocus

Nov 07, 2025

Nov 07, 2025

UBS Adjusts Price Target on Vertex Pharmaceuticals to $546 From $553, Maintains Buy Rating - MarketScreener

Nov 07, 2025

Nov 07, 2025

Vertex Pharmaceuticals Incorporated (VRTX) is Attracting Investor Attention: Here is What You Should Know - Yahoo Finance

Nov 07, 2025

Nov 07, 2025

Top Biotech Stocks To Follow TodayNovember 3rd - MarketBeat

Nov 07, 2025

Nov 06, 2025

Nasdaq, Vertex CEOs talk biotech public markets, AI at Boston event - The Business Journals

Nov 06, 2025

Nov 06, 2025

Agree To Buy Vertex Pharmaceuticals At $290, Earn 6.5% Using Options - Nasdaq

Nov 06, 2025

Nov 06, 2025

Why Vertex Pharmaceuticals Incorporated (VX1) stock signals breakout potential2025 Biggest Moves & Community Trade Idea Sharing Platform - newser.com

Nov 06, 2025

Nov 06, 2025

Evercore ISI Sticks to Their Buy Rating for Vertex Pharmaceuticals (VRTX) - The Globe and Mail

Nov 06, 2025